Oncology / Hematology
Sequential mesenchymal stem cells infusions curbed the incidence and severity of acute and chronic graft-versus-host disease.
Part 1 reviews the staging, prognostic factors, minimal residual disease, and diagnosis in CLL/SLL.
Physician's Weekly provides a roundup of phase 3 clinical trials in non-small cell lung cancer that are currently recruiting.
Patients with hematologic malignancies had significantly reduced physical function prior to undergoing stem cell transplant.
Pembrolizumab effectively shrank or eliminated tumors for 90% of patients with unresectable advanced desmoplastic melanoma
The identification of 91% molecular concordance between endometrial and ovarian carcinomas could help risk-stratify patients.
A panel of experts recently united to release the first comprehensive guidelines for managing patients with MPNs and MDS/MPNs
A survey of adult patients in the Bladder Cancer Advocacy Network revealed differences in unmet needs by patient age and sex.
In this slideshow, we review NCCN guidelines for squamous cell carcinoma of the anal canal (SCAC).
Cheryl Matter, PhD, discusses an AI decision support tool that can improve prostate cancer treatment.
Home-based exercise after lung cancer surgery improved capacity, self-efficacy, and QOL, but not self-reported function.
In pediatric neuroblastoma, inflammatory markers such as the neutrophil-to-lymphocyte ratio predict recurrence and survival.
A half-dose of abiraterone acetate is potentially as safe and effective as the standard dose for mHSPC and mCRPC.
An off-the-shelf immunotherapy that uses allogeneic CAR-NKT cells may improve outcomes for patients with ovarian cancer.
Short-term exposure to polystyrene nanoplastics triggered malignant changes in healthy lung cells, according to research.
Researchers at the 2025 ASCO Annual Meeting identified barriers and solutions to biomarker testing uptake in NSCLC.
Researchers mapped how prostate cancer transforms into its deadliest form, NEPC, revealing a new drug target.
Patients’ autoantibodies may modify their response to cancer checkpoint immunotherapy, according to research.
Just a quarter of clinical trials that led to FDA approval of cancer drugs included those with poor performance status.
As extensive lymph node dissection in NSCLC increases cardiovascular risk, limiting dissection may reduce harm.
180 Mount Airy Road Suite 205
Basking Ridge, NJ 07920
Connect
The content of this site is intended for healthcare professionals.
© 2025 Physician’s Weekly, a Formedics PropertyAny views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Physician’s Weekly, their employees, and affiliates.